Yoshihisa Nakagawa

Prof. Dr. Yoshihisa Nakagawa

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
YOYuki Obayashi
Yuki Obayashi
HSHiroki Shiomi
Hiroki Shiomi
TMTakeshi Morimoto
Takeshi Morimoto
YTYodo Tamaki
Yodo Tamaki
MIMoriaki Inoko
Moriaki Inoko
CICREDO‐Kyoto AMI Registry Wave‐2 Investigators
CREDO‐Kyoto AMI Registry Wave‐2 Investigators
Background: It remains controversial whether long‐term clinical impact of newly diagnosed atrial fibrillation (AF) in the acute phase of acute myocardial infarction (AMI) is different from that of prior AF diagnosed before the onset of AMI. Methods and Results: The current study population from the CREDO‐Kyoto AMI (Coronary Revascularization Demonstrating Outcome Study in Kyoto Acute Myocardial Infarction) Registry Wave‐2 consisted of 6228 patients with AMI who underwent percutaneous coronary intervention. The baseline characteristics and long‐term clinical outcomes were compared according to AF status (newly diagnosed AF: N=489 [7.9%], prior AF: N=589 [9.5%], and no AF: N=5150 [82.7%]). Median follow‐up duration was 5.5 years. Patients with newly diagnosed AF and prior AF had similar baseline characteristics with higher risk profile than those with no AF including older age and more comorbidities. The cumulative 5‐year incidence of all‐cause death was higher in newly diagnosed AF and prior AF than no AF (38.8%, 40.7%, and 18.7%, P <0.001). The adjusted hazard ratios (HRs) for mortality of newly diagnosed AF and prior AF relative to no AF remained significant with similar magnitude (HR, 1.31; 95% CI, 1.12–1.54; P <0.001, and HR, 1.32; 95% CI, 1.14–1.52; P <0.001, respectively). The cumulative 5‐year incidence of stroke decreased in the order of newly diagnosed AF, prior AF and no AF (15.5%, 12.9%, and 6.3%, respectively, P <0.001). The higher adjusted HRs of both newly diagnosed AF and prior AF relative to no AF were significant for stroke, with a greater risk of newly diagnosed AF than that of prior AF (HR, 2.05; 95% CI, 1.56–2.69; P <0.001, and HR, 1.33; 95% CI, 1.00–1.78; P =0.048, respectively). The higher stroke risk of newly diagnosed AF compared with prior AF was largely driven by the greater risk within 30 days. The higher adjusted HRs of newly diagnosed AF and prior AF relative to no AF were significant for heart failure hospitalization (HR, 1.73; 95% CI, 1.35–2.22; P <0.001, and HR, 2.23; 95% CI, 1.82–2.74; P <0.001, respectively) and major bleeding (HR, 1.46; 95% CI, 1.23–1.73; P <0.001, and HR, 1.36; 95% CI, 1.15–1.60; P <0.001, respectively). Conclusions: Newly diagnosed AF in AMI had risks for mortality, heart failure hospitalization, and major bleeding higher than no AF, and comparable to prior AF. The risk of newly diagnosed AF for stroke might be higher than that of prior AF.

1 August 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
YOYuki Obayashi
Yuki Obayashi
HWHirotoshi Watanabe
Hirotoshi Watanabe
TMTakeshi Morimoto
Takeshi Morimoto
KYKo Yamamoto
Ko Yamamoto
MNMasahiro Natsuaki
Masahiro Natsuaki
FIfor the STOPDAPT-2 and STOPDAPT-2 ACS Investigators
for the STOPDAPT-2 and STOPDAPT-2 ACS Investigators
Background: The benefit of clopidogrel monotherapy after 1-month dual antiplatelet therapy (DAPT) compared with 12-month DAPT with aspirin and clopidogrel was demonstrated in the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2), but not in the STOPDAPT-2 acute coronary syndrome (ACS); however, both trials were underpowered based on the actual event rates. Methods: We obtained the prespecified pooled population of 5997 patients as the STOPDAPT-2 total cohort (STOPDAPT-2: N=3009/STOPDAPT-2 ACS: N=2988; ACS: N=4136/chronic coronary syndrome [CCS]: N=1861), comprising 2993 patients assigned to 1-month DAPT followed by clopidogrel monotherapy, and 3004 patients assigned to 12-month DAPT with aspirin and clopidogrel after percutaneous coronary intervention. The primary end point was the composite of cardiovascular (cardiovascular death, myocardial infarction, definite stent thrombosis, or any stroke) or bleeding (Thrombolysis in Myocardial Infarction major/minor) end points at 1 year. Results: One-month DAPT was noninferior to 12-month DAPT for the primary end point (2.84% versus 3.04%; hazard ratio [HR], 0.94 [95% CI, 0.70–1.27]; P noninferiority =0.001; P superiority =0.68). There was no significant risk-difference for the cardiovascular end point between the 1- and 12-month DAPT groups (2.40% versus 1.97%; HR, 1.24 [95% CI, 0.88–1.75]; P noninferiority =0.14; P superiority =0.23). There was a lower risk of the bleeding end point with 1-month DAPT relative to 12-month DAPT (0.50% versus 1.31%; HR, 0.38 [95% CI, 0.21–0.70]; P superiority =0.002). One-month DAPT relative to 12-month DAPT was associated with a lower risk for major bleeding regardless of ACS or CCS (ACS: HR, 0.46 [95% CI, 0.23–0.94]; P =0.03, and CCS: HR, 0.26 [95% CI, 0.09–0.79]; P =0.02; P interaction =0.40), while it was associated with a numerical increase in cardiovascular events in ACS patients, but not in CCS patients, although not statistically significant and without interaction (ACS: HR, 1.50 [95% CI, 0.99–2.27]; P =0.053, and CCS: HR, 0.74 [95% CI, 0.38–1.45]; P =0.39; P interaction =0.08). Conclusions: Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events without being associated with increase in cardiovascular events. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02619760, NCT03462498.

1 February 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
KYKo Yamamoto
Ko Yamamoto
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
HSHiroki Shiomi
Hiroki Shiomi
YTYasuaki Takeji
Yasuaki Takeji
TKTakeshi Kimura
Takeshi Kimura

1 May 2012 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MNMasahiro Natsuaki
Masahiro Natsuaki
YNYoshihisa Nakagawa
Yoshihisa Nakagawa
TMTakeshi Morimoto
Takeshi Morimoto
KOKoh Ono
Koh Ono
SSSatoshi Shizuta
Satoshi Shizuta
TKTakeshi Kimura
Takeshi Kimura

1 October 2023 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
YSYuichi Sawayama
Yuichi Sawayama
NTNaoyuki Takashima
Naoyuki Takashima
AHAkiko Harada
Akiko Harada
YYYuichiro Yano
Yuichiro Yano
TYTakashi Yamamoto
Takashi Yamamoto
YNYoshihisa Nakagawa
Yoshihisa Nakagawa
Aim: To investigate the incidence and in-hospital mortality of acute myocardial infarction (AMI) by conforming to the Universal Definition of Myocardial Infarction (UDMI) in a population-based registry. Methods: The Shiga Stroke and Heart Attack Registry is a multicenter, population-based registry in the Shiga Prefecture, designed to evaluate the incidence and prognosis of acute cerebro-cardiovascular diseases. We registered patients with AMI as defined by the UDMI, who developed AMI from January 2014 to December 2015 in the Shiga Prefecture. The incidence rate of AMI was calculated and standardized for age by a direct method using the 2015 Japanese population. We also evaluated the in-hospital mortality among hospitalized patients with ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI). Results: A total of 1,587 patients were diagnosed with AMI, and the age-adjusted incidence rate was 61.9 per 100,000 person-years. The proportions of patients with STEMI, NSTEMI, and type 3 myocardial infarction were 57%, 30%, and 12%, respectively. The incidence rates of AMI increased with age regardless of sex, which was the highest in those 85 years and older, with 389.7 per 100,000 person-years in men and 221.8 per 100,000 person-years in women. Age-adjusted in-hospital mortality among hospitalized patients with STEMI and NSTEMI was 12.3% and 5.8%, respectively. Conclusions: This population-based registry clarified the age-adjusted incidence rate of AMI under the application of the UDMI, highlighting that in-hospital mortality is still high among patients with STEMI in Japan.

1 March 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
KYKo Yamamoto
Ko Yamamoto
MNMasahiro Natsuaki
Masahiro Natsuaki
TMTakeshi Morimoto
Takeshi Morimoto
HSHiroki Shiomi
Hiroki Shiomi
YMYukiko Matsumura-Nakano
Yukiko Matsumura-Nakano
TKTakeshi Kimura
Takeshi Kimura